- Home
- SOTK vs IMA Comparison
SOTK vs IMA Comparison
Compare SOTK & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOTK | IMA |
|---|---|---|
| Founded | 1975 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 66.3M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOTK | IMA |
|---|---|---|
| Price | $6.29 | $4.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 134.1K | 13.9K |
| Earning Date | 10-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,909,315.00 | $800,000.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $23.41 | N/A |
| P/E Ratio | $87.21 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.40 | $3.90 |
| 52 Week High | $7.48 | $9.10 |
Technical Indicators
Market Signals| Indicator | SOTK | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 19.96 |
| Support Level | $4.07 | $3.92 |
| Resistance Level | $7.48 | $6.10 |
| Average True Range (ATR) | 0.68 | 0.17 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 47.89 | 12.05 |
Price Performance
Historical ComparisonAbout SOTK Sono-Tek Corporation
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.